EP Patent

EP4023228A1 — Genome editing oligonucleotide without programmable nucleases

Assigned to Individual · Expires 2022-07-06 · 4y expired

What this patent protects

The present invention includes compositions and methods for genome editing with in isolated cells or within an organism. The editing oligonucleotides contain an oligonucleotide strand which may contain a linker that positions an editing moiety in the proper location for modifying…

USPTO Abstract

The present invention includes compositions and methods for genome editing with in isolated cells or within an organism. The editing oligonucleotides contain an oligonucleotide strand which may contain a linker that positions an editing moiety in the proper location for modifying the targeted nucleobase and crisprRNA domain and an inactivated Cas 9 domain that cause deamination of the targeted nucleobase. The editing oligonucleotides may also contain at least one nucleotide sequence change from the targeted sequence in the genome. Certain embodiments of the method include modifying a genomic sequence within a cell utilizing an editing oligonucleotide without exogenous proteins to assist in the editing process. The editing oligonucleotide may comprise backbone modifications that increase the nuclease stability of the oligonucleotide as compared to unmodified oligonucleotides.

Drugs covered by this patent

Patent Metadata

Patent number
EP4023228A1
Jurisdiction
EP
Classification
Expires
2022-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.